EGFR and non-small cell lung carcinoma: For instance, anti-EGFR TKIs have been shown to have excellent treatment outcome in patients with EGFR mutation, and we are unable to investigate whether the survival benefit from third-line erlotinib is similar in NSCLC patients with or without EGFR mutation.